Skip to main content
SpringerLink
Log in

Accelerator mass spectrometry analysis of background 14C-concentrations in human blood: aiming at reference data for further microdosing studies

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

Phase 0 clinical studies, which are known as microdose trials, are expected to promote drug development and reduce development costs. The accelerator mass spectrometry (AMS) system is expected to play an important role in the microdosing tests, as it is a highly sensitive measurement system that can be used to determine the drug concentrations in these tests. Using the AMS system, we measured the background 14C-concentration in human blood and evaluated the data for use as a reference in microdose studies that administer 14C-labeled compounds in humans.

Methods

Blood samples of five healthy Japanese volunteers (three men, two women, median age 40.4 ± 9.8 years) were collected around the same time and just prior to when the subjects ate a meal (between 12:00 noon and 2:00 pm). Centrifugal separations of blood that was allowed to clot and the plasma were performed at 503 g for 2 min at 4°C. Background 14C-concentration for each of the samples was measured using the AMS system. The Institute of Accelerator Analysis, which is the first contract research organization in Japan that is capable of providing AMS analysis services for carbon dating and bioanalysis work, performed the AMS analysis.

Results

The mean 14C-concentration in blood was 1.613 ± 0.125 dpm/ml (men 1.668 ± 0.114 dpm/ml, women 1.514 ± 0.076 dpm/ml), in clots 2.373 ± 0.087 dpm/ml (men 2.381 ± 0.101 dpm/ml, women 2.357 ± 0.060 dpm/ ml), and in plasma 0.648 ± 0.049 dpm/ml (men 0.647 ± 0.059 dpm/ml, women 0.649 ± 0.032 dpm/ml). The coefficient variation (CV) for blood was 7.8% (men 6.9%, women 5.0%), for clots 3.7% (men 4.3%, women 2.5%), and for plasma 7.6% (men 9.1%, women 4.9%). The 14C-concentrations of the clot and blood were higher than those of plasma. The 14C-concentrations in the blood and plasma were slightly different between individuals when compared with the values for the clot, although the differences were quite small, with a CV value less than 7.8%.

Conclusions

Even though the 14C-concentration differed only slightly between individuals, 14C-concentrations of the clot and blood were higher than those of the plasma. Therefore, the variation and difference of the background data for blood and plasma might be of use as a reference for microdosing test evaluations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Vogel JS, Turteltaub KW. Accelerator mass spectrometry as a bioanalytical tool for nutritional research. Adv Exp Med Biol 1998;445:397–410.

    PubMed  CAS  Google Scholar 

  2. Garner RC, Barker J, Flavell C, Garner JV, Whattam M, Young GC, et al. A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14Clabelled drugs in plasma, urine and faecal extracts. J Pharm Biomed Anal 2000;24:197–209.

    Article  PubMed  CAS  Google Scholar 

  3. Nelson DE, Korteling RG, Stott WR. Carbon-14: direct detection at natural concentration. Science 1977;198:507–508.

    Article  PubMed  CAS  Google Scholar 

  4. Bennett CL, Beukens RP, Clover MR, Gove HE, Liebert RB, Litherland AE, et al. Radiocarbon dating using electrostatic accelerators: negative ions provide the key. Science 1977;198: 508–510.

    Article  PubMed  CAS  Google Scholar 

  5. Miyaoka T, Isono Y, Setani K, Sakai K, Yamada I, Sato Y, et al. Bioanalysis works in the IAA AMS facility: comparison of AMS analytical method with LSC method in human mass balance study. Nucl Instr Methods Phys Res 2007;B259: 779–785.

    Article  Google Scholar 

  6. Vogel JS, Turteltaub KW, Finkel R, Nelson DE. Accelerator mass spectrometry. Anal Chem 1995;67:353A–359A.

    Article  PubMed  CAS  Google Scholar 

  7. Kaye B, Garner RC, Mauthe RJ, Freeman SP, Turteltaub KW. A preliminary evaluation of accelerator mass spectrometry in the biomedical field. J Pharm Biomed Anal 1997;16:541–543.

    Article  PubMed  CAS  Google Scholar 

  8. Japan Pharmaceutical Manufactures Association. DATA BOOK 2000. Tokyo: Japan Pharmaceutical Manufactures Association; 2000. p 1–42.

    Google Scholar 

  9. The European Agency for the Evaluation of Medical products. Evaluation of Medicines for Human Use (EMEA), Committee for Proprietary Medicinal Products (CPMP). Position paper on non-clinical safety studies to support clinical trials with a single microdose, CPMP/SWP/2599/02, London, 23 January 2003; revised edition: CPMP/SWP/2599/02/Rev 1, London, 23 June 2004.

  10. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry, investigators and reviewers, exploratory IND studies, 12 January 2006.

  11. Kitagawa H, Masuzawa T, Nakamura T, Matsumoto E. A batch preparation method for graphite targets with low background for AMS 14C measurements. Radiocarbon 1993; 35:295.

    CAS  Google Scholar 

  12. Twombly R. Slow start to Phase 0 as researchers debate value. J Natl Cancer Drugs 2006;9:115–122.

    Google Scholar 

  13. Goodall S. Raising to the productivity challenge: a strategic framework for Biopharma. Boston Consulting Group Report. 2004. http://www.bcg.com/publications/files/rising_to_the_productivity_challenge.pdf.

  14. Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2003;2:233–240.

    Article  PubMed  CAS  Google Scholar 

  15. Combes RD, Berridge T, Connelly J, Eve MD, Garner RC, Toon S, et al. Early microdose drug studies in human volunteers can minimise animal testing: proceedings of a workshop organised by volunteers in research and testing. Eur J Pharm Sci 2003;19:1–11.

    Article  PubMed  CAS  Google Scholar 

  16. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. 21 July 2005.

  17. Garner RC. Accelerator mass spectrometry in pharmaceutical research and development: a new ultrasensitive analytical method for isotope measurement. Curr Drug Metab 2000;1: 205–213.

    Article  PubMed  CAS  Google Scholar 

  18. The European Agency for the Evaluation of Medical Products. Evaluation of Medicines for Human Use (EMEA), Committee for Proprietary Medicinal Products (CPMP). Concept paper on the development of CHMP guideline on the non-clinical requirement to support early phase I:. clinical trials with pharmaceutical compounds London, 23 March 2006 Doc. Ref. EMEA/CHMP/SWP/91850/2006.

  19. Marchetti S, Schellens JH. The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials. Br J Cancer 2007;97:577–581.

    Article  PubMed  CAS  Google Scholar 

  20. Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, et al. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs. Clin Pharmacol Ther 2006;80:203–215.

    Article  PubMed  CAS  Google Scholar 

  21. Fuma S, Inoue Y, Miyamoto K, Takeda H, Iwakura T, Arai K, et al. Environmental background 14C levels in Japan in 1990s. Radioisotopes 2002;51:381–391.

    CAS  Google Scholar 

  22. Harkness DS, Walton A. Carbon-14 in the biosphere and humans. Nature 1969;223:1216–1218.

    Article  PubMed  CAS  Google Scholar 

  23. Young G, Ellis W, Ayrton J, Hussey E, Adamkiewicz B. Accelerator mass spectrometry (AMS): recent experience of its use in a clinical study and the potential future of the technique. Xenobiotica 2001;31:619–632.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiology, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan

    Ryogo Minamimoto, Keisuke Yoshida, Takashi Oka & Tomio Inoue

  2. Institute of Accelerator Analysis (IAA) Ltd., Kawasaki, Japan

    Yoshimi Hamabe, Teiji Miyaoka & Takamitsu Hara

  3. Bay Bio Imaging (BBI) Co. Ltd., Yokohama, Japan

    Takashi Oka

Authors
  1. Ryogo Minamimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshimi Hamabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Teiji Miyaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takamitsu Hara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keisuke Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Takashi Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomio Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryogo Minamimoto.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Minamimoto, R., Hamabe, Y., Miyaoka, T. et al. Accelerator mass spectrometry analysis of background 14C-concentrations in human blood: aiming at reference data for further microdosing studies. Ann Nucl Med 22, 883–889 (2008). https://doi.org/10.1007/s12149-008-0200-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-008-0200-x

Keywords

Search

Navigation